Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Benthe B. Muntinghe-Wagenaar; T. Jeroen N. Hiltermann

doi:10.21037/tlcr-24-966

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Benthe B. Muntinghe-Wagenaar, T. Jeroen N. Hiltermann^*

^*Corresponding author voor dit werk

Translational Immunology Groningen (TRIGR)

Onderzoeksoutput: Editorial › Academic › peer review

53 Downloads (Pure)

Originele taal-2	English
Pagina's (van-tot)	328-333
Aantal pagina's	6
Tijdschrift	Translational lung cancer research
Volume	14
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.21037/tlcr-24-966
Status	Published - 28-feb.-2025

Toegang tot document

10.21037/tlcr-24-966Licentie: CC BY-NC-ND

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancerFinal publisher's version, 195 KBLicentie: CC BY-NC-ND

Handle.net

Permanente koppeling

Andere bestanden en links

Link naar publicatie in Scopus

TLCR Outstanding Author interview
Hiltermann, T. J. N.
24/02/2025
1 Mediabijdrage
Pers / media: Expert Comment › Professional

TLCR Outstanding Author
Hiltermann, J. (Recipient), mrt.-2025
Prijs: Prize › Academic

Bestand

Citeer dit

@article{bd004fad510241c98ccad25ff6485602,

title = "Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?",

keywords = "biomarker, Immune checkpoint inhibition, non-small cell lung cancer (NSCLC), programmed death-ligand 1 (PD-L1)",

author = "Muntinghe-Wagenaar, \{Benthe B.\} and Hiltermann, \{T. Jeroen N.\}",

year = "2025",

month = feb,

day = "28",

doi = "10.21037/tlcr-24-966",

language = "English",

volume = "14",

pages = "328--333",

journal = "Translational lung cancer research",

issn = "2218-6751",

publisher = "AME PUBL CO",

number = "2",

}

TY - JOUR

T1 - Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer

T2 - towards biomarker-driven therapies?

AU - Muntinghe-Wagenaar, Benthe B.

AU - Hiltermann, T. Jeroen N.

PY - 2025/2/28

Y1 - 2025/2/28

KW - biomarker

KW - Immune checkpoint inhibition

KW - non-small cell lung cancer (NSCLC)

KW - programmed death-ligand 1 (PD-L1)

UR - http://www.scopus.com/inward/record.url?scp=85219580293&partnerID=8YFLogxK

U2 - 10.21037/tlcr-24-966

DO - 10.21037/tlcr-24-966

M3 - Editorial

AN - SCOPUS:85219580293

SN - 2218-6751

VL - 14

SP - 328

EP - 333

JO - Translational lung cancer research

JF - Translational lung cancer research

IS - 2

ER -

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Toegang tot document

Handle.net

Andere bestanden en links

Pers/Media

TLCR Outstanding Author interview

Prijzen

TLCR Outstanding Author

Citeer dit